Quality of life in the SMARTEST study

Project description

This is part of the SMARTEST study.

The aim of this sub-study is to determine whether treatment satisfaction and health related quality of life differ between dapagliflozin and metformin treatment in patients with early type 2 diabetes. Participants are asked to complete the DTSQ that measures treatment satisfaction at start, 3 months and 1 year after enrolment, and RAND-36 (1b) that measures HRQL at start, after 1 and 2 years.